Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-01-21
2011-10-18
Wen, Sharon (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388150, C424S130100, C424S135100, C424S141100, C424S142100, C424S143100, C435S007100
Reexamination Certificate
active
08039598
ABSTRACT:
Antibody fragments (Fabs and scFvs) specific to the Met receptor are disclosed. Compositions and kits including these Fabs and scFvs, and drug and imaging conjugates of these Fabs and scFvs also are disclosed. The novel Fabs and scFvs can be internalized into the interior of a cell. Methods include using the novel Met Fabs and scFvs for diagnosing, prognosing, and treating cancer, and for evaluating chemotherapeutic response.
REFERENCES:
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. BBRC 2003, 307:198-205.
Vajdos et al. J. Mol. Biol. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Padlan et al. PNAS 1989, 86:5938-5942.
Lamminmaki et al. JBC 2001, 276:36687-36694.
Watkins, N. A, et al. “Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion”. Blood. 102(2): 718-24 (Jul. 15, 2003).
Weiner, L., et al. “Tunable antibodies”. Nature Biotech 23(5): 556-557 (May 2005).
Weissleder, R., et al. “In vivo imaging of tumors with protease-activated near-infrared fluorescent probes”. Nature Biotech. 17: 375-378 (1999).
Wilson, I. A. et al. “Antibody-antigen interactions: new structures and new conformational changes”. Curr. Opin. Struct. Biol. 4: 857-867 (1994).
Wu, A.M., et al. “Arming antibodies: prospects and challenges for immunoconjugates”. Nature Biotech 23:1137-46 (Sep. 2005).
Zemlin, M., et al. “Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit Distinct Repertoires that Differ in their Amino Acid Composition and Predicted Range of Structures”. J. Mol. Biol. 334: 733-749 (2003).
Program and Abstracts, Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates. Cancer Biotherapy & Radiopharmaceuticals 17:465-494 (2002).
Huls, G. et al. “Tumor cell killing by in vitro affinity-matured recombinant human monoclonal antibodies”. Cancer Immunol Immunother 50: 163-171 (2001).
Gura, T. “Magic Bullets hit the target”. Nature 417: 584-586 (Jun. 6, 2002).
Adams, G., et al, “High Affinity Restricts the Localization and Tumor Penetration of Single-Chain Fv Antibody Molecules”. Cancer Res. 61: 4750-4755 (Jun. 15, 2001).
Altschul, S., et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”. Nucleic Acids Res. 25 (No. 17): 3389-3402 (1997).
Baneyx, F., et al. “Recombinant protein folding and misfolding inEscherichia coli”. Nature Biotech. 22: 1399-1408 (Nov. 2004).
Batzer, M., et al. “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'sterminus”. Nucleic Acid Res. 19: 5081 (1991).
Begent, RH., et al. “Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library”. Nat Med. 2: 979-984 (Sep. 1996).
Berzofsky, J., et al. “Antibody-Antigen Interactions and Monoclonal Antibodies”. Fundamental Immunology Paul, W E , Ed , Raven Press New York, N Y (1984).
Birchmeier, C., et al. “Met, Metastasis, Motility and More”. Nat. Rev. Mol. Cell Biol. 4: 915-925 (Dec. 2003).
Bird, R., et al. “Single-Chain Antigen-Binding Proteins”. Science 242: 423-426 (Oct. 21, 1988).
Bruchez, M., et al. “Semiconductor Nanocrystals as Fluorescent Biological Labels”. Science 281: 2013-2016 (Sep. 25, 1998).
Cao, B., et al. “Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models”. Proc. Natl. Acad. Sci. USA 98: 7443-7448 (Jun. 19, 2001).
Chan, W., et al. Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection. Science 281: 2016-2018 (1998).
Devereux, J., et al. “A comprehensive set of sequence analysis programs for the VAX”. Nucleic Acids Res. 12 (1): 387-395 (1984).
Groner, B., et al. “Therapeutic Antibodies”. Current Molecular Medicine 4: 539-547 (2004).
Guillemard, V., et al. “Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity”. Oncogene 23: 3613-3621 (Mar. 22, 2004).
Guillemard, V., et al. “Taxane-Antibody Conjugates Afford Potent Cytotoxicity, Enhanced Solubility, and Tumor Target Selectivity”. Cancer Res 61: 694-699 (Jan. 15, 2001).
Heitner, T., et al. “Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library”. J. Immunol. Methods. 248: 17-30 (2001).
Holliger, P., et al. “Engineered antibody fragments and the rise of single domains”. Nature Biotechnology 23: 1126-36 (Sep. 2005).
Hoogenboom, H.R. “Designing and optimizing library selection strategies for generating high-affinity antibodies”. Trends Biotechnol. 15: 62-70 (Feb. 1997).
Hudson, P.J., et al. “Engineered Antibodies”. Nat Med. 9: 129-34 (Jan. 2003).
Huls, G.A. et al. “A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments”. Nat Biotechnol.17: 276-81 (Mar. 1999).
Huston, J., et al. “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”. Proc. Natl. Acad. Sci. USA 85: 5879-5883 (Aug. 1988).
Iyer, M., et al. 8-[18F] Fluoropenciclovir: An Improved Reporter Probe for Imaging HSV1-tk Reporter Gene Expression In Vivo Using PET. J Nucl Med 42: 96-105 (Jan. 2001).
Jakobovits, A., “Production of fully human antibodies by transgenic mice”. Curr Opin Biotechnol 6: 561-566 (1995).
Jones PT., et al. “Replacing the complementarity-determining regions in human antibody with those from a mouse”. Nature 321: 522-525 (1986).
Karlin, S., et al. “Applications and statistics for multiple high-scoring segments in molecular sequences”. Proc. Natl. Acad. Sci. USA 90: 5873-5877 (Jun. 1993).
Kohler, G., et al. “Continuous cultures of fused cells secreting antibody of predefined specificity”. Nature 256: 495-497 (Aug. 7, 1975).
Kohls, M., et al. “Mab-Zap: A Tool for Evaluating Anitbody Efficacy for Use in an Immunotoxin”. Biotechniques 28: 162-165 (Jan. 2000).
Lee, C., et al. “High-affinity Human Anitbodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold”. J. Mol. Biol. 340: 1073-1093 (2004).
Liu, B., et al. “Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells”. Cancer Res. 64: 704-710 (Jan. 15, 2004).
Liu, Y., et al. “Recombinant Single-Chain Antibody Fusion Construct Targeting Human Melanoma Cells and Containing Tumor Necrosis Factor”. Int J Cancer 108: 549-557 (2004).
Lu, J., et al. “An alternating selection strategy for cloning phage display antibodies”. Journal of Immunological Methods 228: 109-119 (1999).
Lui, V.W., et al. “EGFR-Mediated Cell Cycle Regulation”. Anticancer Res. 22: 1-11 (2002).
Mamot C., et al. “Epidermal Growth Factor Receptor-Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs In vivo”. Cancer Res 65: 11631-11638 (Dec. 15, 2005).
Nguyen, T. H., et al. “Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met”. Cancer Gene Ther. 10: 840-849 (2003).
Ohashi, K., et al. “Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses”. Nat. Med. 6: 327-331 (Mar. 2000).
Ohtsuka, E., et al. “An Alternative Approach to
Honigman Miller Shwartz & Cohn LLP
Siegel Douglas H.
Van Andel Research Institute
Wen Sharon
LandOfFree
Met fab and SCFV fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Met fab and SCFV fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Met fab and SCFV fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271941